

Edgar Filing: DAVOX CORP - Form 8-K

Promptly after the effective time of the merger, Davox will issue an aggregate of 544,366 shares of Davox common stock, par value \$0.10 per share, and \$9,259,313 in cash in exchange for all of the outstanding shares of capital stock of CellIt. Pursuant to the terms of the Merger Agreement, each outstanding share of capital stock of CellIt converted into the right to receive the following consideration:

- . Each outstanding share of CellIt Series A Preferred Stock was converted into the right to receive approximately 0.019 shares of Davox common stock and approximately \$.269 in cash.
- . Each outstanding share of CellIt Series B Preferred Stock was converted into the right to receive approximately 0.044 shares of Davox common stock and approximately \$.625 in cash.
- . Each outstanding share of CellIt Common Stock was converted into the right to receive a cash payment equal to approximately \$0.095.

Additionally, pursuant to the terms of the Merger Agreement, Davox made payments totaling \$920,741 to satisfy certain obligations of Cellit.

Each holder of CellIt capital stock who is otherwise entitled to a fraction of a share of Davox common stock will receive cash in lieu thereof. In accordance with the terms of the Merger Agreement and an Escrow Agreement, an aggregate of \$2,230,000 in cash has been placed in an escrow account to secure certain indemnification obligations of CellIt under the Merger Agreement.

The Davox common stock issued in connection with the merger was issued in reliance on the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended. Davox used available cash on hand to pay for the cash portion of the merger consideration. The purchase price and terms for the transaction were determined in arms-length negotiations. Davox will account for the transaction under the purchase method of accounting.

The terms of the merger are more fully described in the Merger Agreement and the Registration Rights Agreement, which are filed as Exhibits 2.1 and 10.1, respectively, and incorporated herein by reference.

Item 7. Financial Statements, Pro Forma Financial Information and

Exhibits.

(a) Financial Statements of Business Acquired.

It is impracticable to provide the financial statements required by Item 7(a) of Form 8-K relating to the merger at the time this report is filed. Such required financial information will be filed as soon as practicable, but not later than March 29, 2002.

-3-

(b) Pro Forma Financial Information.

It is impracticable to provide the pro forma financial information

Edgar Filing: DAVOX CORP - Form 8-K

required by Item 7(b) of Form 8-K relating to the merger at the time this report is filed. Such required pro forma financial information will be filed as soon as practicable, but not later than March 29, 2002.

(c) Exhibits.

Exhibit No. -----	Description -----
2.1	Agreement and Plan of Merger dated as of January 10, 2002 by and among Davox Corporation, AP Acquisition Corp., and CellIt, Inc.
10.1	Registration Rights Agreement dated as of January 14, 2002, by and among Davox Corporation and certain former stockholders of CellIt, Inc.
99.1	Press Release dated as of January 10, 2002
99.2	Press Release dated as of January 16, 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DAVOX CORPORATION

January 28, 2002

By: /s/ James D. Foy

James D. Foy
President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No. -----	Description -----
2.1	Agreement and Plan of Merger dated as of January 10, 2002 by and among Davox Corporation, AP Acquisition Corp., and CellIt, Inc.
10.1	Registration Rights Agreement dated as of January 14, 2002, by and among Davox Corporation and certain former stockholders of CellIt, Inc.
99.1	Press Release dated as of January 10, 2002.
99.2	Press Release dated as of January 16, 2002.